Zynacort

Oral Prednisolone Solution (as Sodium Phosphate)
15 mg / 5 ml

Product Features: Supplied with an oral dosing adaptor and a 5 ml syringe for accurate dosing; berry-flavored for improved pediatric compliance.

Indications in Pediatric Neurology Neuromuscular and Peripheral Nervous System Disorders:
Myasthenia gravis, Duchenne muscular dystrophy, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bell’s palsy
Central Nervous System Inflammatory and Demyelinating Disorders:
Acute disseminated encephalomyelitis (ADEM), Optic neuritis, Transverse myelitis, Central nervous system vasculitis, Autoimmune encephalitis
Epileptic and Pediatric Neurological Disorders:
Infantile spasms (West syndrome), Lennox–Gastaut syndrome, Epileptic encephalopathy with electrical status epilepticus during sleep (ESES / CSWS)

Dosage and Administration: Dosage and duration of treatment should be individualized based
on the patient’s clinical condition, disease severity, and physician’s clinical judgment.
Common Adverse Effects
• Short-term: Insomnia, irritability, increased appetite, hyperglycemia
• Long-term: Growth suppression, osteoporosis, hypertension,
recurrent infections, glaucoma
• Gastrointestinal: Nausea, abdominal pain, gastric ulcer
Drug Interactions
• Oral anticoagulants (may increase bleeding risk)
• Diuretics (risk of electrolyte imbalance, especially hypokalemia)
• Antidiabetic agents (may reduce efficacy)
• Anticonvulsants (may alter prednisolone metabolism and reduce
therapeutic efficacy)

References:
1. Swaiman’s Pediatric Neurology: Principles and Practice. 7th ed. Elsevier Health Sciences; 2025.
2. Fenichel’s Clinical Pediatric Neurology. 9th ed. Elsevier; 2024.